The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
Product definition
What is 2X Blend CJC-1295 Without DAC / Ipamorelin?
The 2X Blend combines CJC-1295 Without DAC and Ipamorelin — the standard GHRH+GHRP research combination producing synergistic, selective GH pulse amplification through two independent receptor systems.
The 2X Blend is a pre-combined formulation of CJC-1295 Without DAC (MOD GRF 1-29) and Ipamorelin designed for the standard GHRH+GHRP pulsatile GH research protocol. The combination reflects the convergence of two independent lines of GH axis pharmacology research:
GRHH receptor pharmacology: GHRH analogs (CJC-1295 Without DAC) act on the GHRH receptor to increase somatotrope responsiveness and the available pool of GH ready for release per pulse.
GH secretagogue receptor pharmacology: GHRPs (Ipamorelin) act on GHS-R1a to trigger GH release directly through a calcium-signaling pathway, independent of GHRH receptor input.
When both receptor systems are activated simultaneously, the resulting GH pulse is significantly larger than either system alone — a synergistic effect documented in rodent GH pulse studies. The 2X Blend pre-combines these compounds in a single lyophilized vial to reduce preparation complexity for labs running this standard research protocol.
Ipamorelin's selection as the GHRP component (versus GHRP-2 or GHRP-6) is deliberate: its GH selectivity profile keeps the combination's endpoint attributable to GH-axis effects, maintaining research interpretability when the study endpoint is downstream GH or IGF-1 signaling rather than broad pituitary hormone secretagogue pharmacology.
Research context
How is 2X Blend CJC-1295 Without DAC / Ipamorelin described in the research literature?
CJC-1295 Without DAC activates GHRH receptors (somatotrope priming, pulse amplitude baseline); Ipamorelin activates GHS-R1a (pulse magnitude amplification) — two mechanistically independent receptor pathways. Combined, they produce synergistic GH release greater than either alone. Ipamorelin's GH selectivity (no cortisol/prolactin co-stimulation) keeps the GH endpoint clean for research interpretation.
Compound profile
Key facts about 2X Blend CJC-1295 Without DAC / Ipamorelin
- Components
- CJC-1295 Without DAC (MOD GRF 1-29) + Ipamorelin
- CJC mechanism
- GHRH receptor agonist — somatotrope priming (~30 min half-life)
- Ipamorelin mechanism
- GHS-R1a agonist — GH pulse amplification (~2 hr half-life, GH selective)
- Combined effect
- Synergistic GH release greater than either compound alone
- Research category
- GH axis, pulsatile GH, GHRH+GHRP combination pharmacology
- Format
- Lyophilized blend (single vial)
- Storage
- Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days
Research areas
What research areas is 2X Blend CJC-1295 Without DAC / Ipamorelin associated with?
- Standard GHRH+GHRP combination for pulsatile GH research — the most commonly used two-compound GH protocol
- Synergistic GH release: combined administration produces greater GH output than either compound alone
- Mechanistically independent receptor systems: GHRH receptor (CJC-1295 Without DAC) + GHS-R1a (Ipamorelin)
- Ipamorelin's GH selectivity preserves research interpretability — no cortisol/prolactin confounders
- Pre-combined single vial — reduces preparation complexity for standard GH axis research protocols
- ~30-minute matched half-lives for both components — synchronized pharmacokinetic window for GH pulse research
Research audience
Who researches 2X Blend CJC-1295 Without DAC / Ipamorelin?
The 2X Blend is used by researchers studying GH pulse amplitude pharmacology, GHRH+GHRP synergistic mechanisms, pituitary somatotrope biology, GH axis dose-response relationships, and GH-dependent downstream signaling (IGF-1, anabolic pathway). It is the appropriate combination when selective pulsatile GH research is the protocol objective.
Preclinical research overview
What does the preclinical literature say about 2X Blend CJC-1295 Without DAC / Ipamorelin?
The GHRH+GHRP combination protocol emerged from the observation that GHRH and GHRP activate GH release through pharmacologically independent pathways that produce additive or synergistic effects. Early characterization in rodent models showed that simultaneous GHRH + GHRP-6 administration produced GH pulses larger than either compound alone, establishing the synergy principle. Subsequent research confirmed the synergy across multiple GHRH and GHRP compound combinations.
The selection of ipamorelin as the optimal GHRP partner for this combination protocol came from comparative selectivity studies (discussed in the ipamorelin product description): ipamorelin produces equivalent or superior GH release to GHRP-2 and GHRP-6 with dramatically lower cortisol and prolactin co-stimulation. In GH axis research where the downstream endpoint is GH-specific effects (IGF-1, muscle protein synthesis markers, body composition), the absence of cortisol confounders in ipamorelin-containing protocols produces cleaner, more interpretable results.
The 2X Blend designation reflects both compounds' presence in a single preparation. In research protocol design, the key variable to titrate is the dose of each component and the administration frequency relative to the study endpoint — the pre-combined format ensures consistent dose ratios across protocol timepoints.
Common questions
Frequently asked about 2X Blend CJC-1295 Without DAC / Ipamorelin
Why is Ipamorelin the preferred GHRP partner rather than GHRP-2?
GHRP-2 produces higher peak GH responses at equivalent doses but also significantly elevates cortisol and prolactin. When the research endpoint is GH-specific downstream effects (IGF-1, anabolic signaling), GHRP-2's cortisol co-stimulation adds a confounding variable that must be controlled. Ipamorelin's selective GH response — without cortisol or prolactin elevation at GH-effective doses — keeps the combination's pharmacological effect attributable to GH axis activation. GHRP-2 is appropriate when maximum GH output is required and cortisol co-stimulation is acceptable or is itself an endpoint.
Does combining the compounds in one vial affect their individual stability?
CJC-1295 Without DAC and Ipamorelin are stable in combination when lyophilized together. The pre-combined lyophilized form maintains both compounds' stability at −20°C. Once reconstituted, the combined solution should be stored at 2–8°C and used within 30 days. No evidence of compound-compound interaction or cross-degradation in the combined formulation has been documented in the published literature.
When would researchers use the individual compounds separately rather than the 2X Blend?
The 2X Blend is appropriate when both compounds are always administered together in the same dose and protocol. Individual compounds are preferred when: (1) studying either compound's isolated pharmacology; (2) using different doses of each component than the pre-combined ratio; (3) titrating each component independently across a dose-response study; or (4) pairing CJC-1295 Without DAC with a different GHRP than ipamorelin. The pre-combined format optimizes convenience for standard fixed-ratio combination protocols.
Available now
Live alternatives from this research category
These products from the same research category are currently available for ordering.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy